High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

Sherif Farag, B. J. Bolwell, P. J. Elder, M. Kalaycio, T. Lin, B. Pohlman, S. Penza, G. Marcucci, W. Blum, R. Sobecks, B. R. Avalos, J. C. Byrd, E. Copelan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n=127) or BuCy2 (n=110). The 5-year survival was 27.3 and 30.1% following BuCyVP and BuCy2, respectively (P=0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8% with BuCyVP and BuCy2 (P=0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P=0.002) and from related donors (P=0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P=0.002). In a separate analysis of CR1 patients (n=56), there was no significant difference in survival (P=0.37) or CIR (P=0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P=0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P=0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalBone Marrow Transplantation
Volume35
Issue number7
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Busulfan
Stem Cell Transplantation
Etoposide
Acute Myeloid Leukemia
Cyclophosphamide
Recurrence
Survival
Incidence
Transplants
Homologous Transplantation
Tissue Donors

Keywords

  • Allogeneic stem cell transplantation
  • AML
  • Etoposide

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. / Farag, Sherif; Bolwell, B. J.; Elder, P. J.; Kalaycio, M.; Lin, T.; Pohlman, B.; Penza, S.; Marcucci, G.; Blum, W.; Sobecks, R.; Avalos, B. R.; Byrd, J. C.; Copelan, E.

In: Bone Marrow Transplantation, Vol. 35, No. 7, 04.2005, p. 653-661.

Research output: Contribution to journalArticle

Farag, S, Bolwell, BJ, Elder, PJ, Kalaycio, M, Lin, T, Pohlman, B, Penza, S, Marcucci, G, Blum, W, Sobecks, R, Avalos, BR, Byrd, JC & Copelan, E 2005, 'High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia', Bone Marrow Transplantation, vol. 35, no. 7, pp. 653-661. https://doi.org/10.1038/sj.bmt.1704867
Farag, Sherif ; Bolwell, B. J. ; Elder, P. J. ; Kalaycio, M. ; Lin, T. ; Pohlman, B. ; Penza, S. ; Marcucci, G. ; Blum, W. ; Sobecks, R. ; Avalos, B. R. ; Byrd, J. C. ; Copelan, E. / High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 7. pp. 653-661.
@article{97375fb3fe444cb1b7e65d5d2d9ce33f,
title = "High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia",
abstract = "To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n=127) or BuCy2 (n=110). The 5-year survival was 27.3 and 30.1{\%} following BuCyVP and BuCy2, respectively (P=0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8{\%} with BuCyVP and BuCy2 (P=0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P=0.002) and from related donors (P=0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P=0.002). In a separate analysis of CR1 patients (n=56), there was no significant difference in survival (P=0.37) or CIR (P=0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P=0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P=0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.",
keywords = "Allogeneic stem cell transplantation, AML, Etoposide",
author = "Sherif Farag and Bolwell, {B. J.} and Elder, {P. J.} and M. Kalaycio and T. Lin and B. Pohlman and S. Penza and G. Marcucci and W. Blum and R. Sobecks and Avalos, {B. R.} and Byrd, {J. C.} and E. Copelan",
year = "2005",
month = "4",
doi = "10.1038/sj.bmt.1704867",
language = "English (US)",
volume = "35",
pages = "653--661",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

AU - Farag, Sherif

AU - Bolwell, B. J.

AU - Elder, P. J.

AU - Kalaycio, M.

AU - Lin, T.

AU - Pohlman, B.

AU - Penza, S.

AU - Marcucci, G.

AU - Blum, W.

AU - Sobecks, R.

AU - Avalos, B. R.

AU - Byrd, J. C.

AU - Copelan, E.

PY - 2005/4

Y1 - 2005/4

N2 - To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n=127) or BuCy2 (n=110). The 5-year survival was 27.3 and 30.1% following BuCyVP and BuCy2, respectively (P=0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8% with BuCyVP and BuCy2 (P=0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P=0.002) and from related donors (P=0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P=0.002). In a separate analysis of CR1 patients (n=56), there was no significant difference in survival (P=0.37) or CIR (P=0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P=0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P=0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.

AB - To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n=127) or BuCy2 (n=110). The 5-year survival was 27.3 and 30.1% following BuCyVP and BuCy2, respectively (P=0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8% with BuCyVP and BuCy2 (P=0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P=0.002) and from related donors (P=0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P=0.002). In a separate analysis of CR1 patients (n=56), there was no significant difference in survival (P=0.37) or CIR (P=0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P=0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P=0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.

KW - Allogeneic stem cell transplantation

KW - AML

KW - Etoposide

UR - http://www.scopus.com/inward/record.url?scp=20244373795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244373795&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704867

DO - 10.1038/sj.bmt.1704867

M3 - Article

C2 - 15711571

AN - SCOPUS:20244373795

VL - 35

SP - 653

EP - 661

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -